These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 31307348)

  • 1. On Drugs: Preemption, Presumption, and Remedy.
    McCuskey EY
    J Leg Med; 2018; 38(3-4):365-385. PubMed ID: 31307348
    [No Abstract]   [Full Text] [Related]  

  • 2. Regulating the safety of pharmaceuticals: the FDA, preemption, and the public's health.
    Gostin LO
    JAMA; 2009 May; 301(19):2036-7. PubMed ID: 19454642
    [No Abstract]   [Full Text] [Related]  

  • 3. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.
    Dorfman HL; Quinn VM; Brophy EA
    Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765
    [No Abstract]   [Full Text] [Related]  

  • 4. Risk, responsibility, and generic drugs.
    Kesselheim AS; Avorn J; Greene JA
    N Engl J Med; 2012 Nov; 367(18):1679-81. PubMed ID: 23113477
    [No Abstract]   [Full Text] [Related]  

  • 5. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 6. The case for preemption of prescription drug failure-to-warn claims.
    Kim CH
    Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969
    [No Abstract]   [Full Text] [Related]  

  • 7. Legal Liability of Generic vs Brand Drug Manufacturers for Inadequate Product Labels.
    Boumil MM; Curfman G
    JAMA; 2018 Aug; 320(6):547-548. PubMed ID: 30039167
    [No Abstract]   [Full Text] [Related]  

  • 8. Who is now responsible for discovering and warning about adverse effects of generic drugs?
    Kesselheim AS; Green MD; Avorn J
    JAMA; 2013 Sep; 310(10):1023-4. PubMed ID: 23922000
    [No Abstract]   [Full Text] [Related]  

  • 9. Dual regulatory pharmaceutical labeling schemes; the role of the Federal Preemption Doctrine.
    Fern FH; Bartell L
    Health Matrix; 1987; 5(3):17-23. PubMed ID: 10285381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The demise of drug design litigation: death by federal preemption.
    Twerski AD
    Am Univ Law Rev; 2018; 68(1):281-304. PubMed ID: 30457769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceutical and Medical Devices: FDA Oversight.
    White RS;
    Issue Brief Health Policy Track Serv; 2015 Dec; ():1-97. PubMed ID: 27116797
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmaceuticals and medical devices: cost savings.
    ; Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-37. PubMed ID: 22403843
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmaceuticals and medical devices: cost savings. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2010 Jan; ():1-18. PubMed ID: 20213921
    [No Abstract]   [Full Text] [Related]  

  • 14. On access and accountability--two Supreme Court rulings on generic drugs.
    Boumil MM; Curfman GD
    N Engl J Med; 2013 Aug; 369(8):696-7. PubMed ID: 23923990
    [No Abstract]   [Full Text] [Related]  

  • 15. Federal preemption of common law tort awards by the Federal Food, Drug, and Cosmetic Act.
    Carrier MK
    Food Drug Law J; 1996; 51(4):509-611. PubMed ID: 11797729
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmaceuticals and medical devices: cost savings. End-of-year issue brief.
    Health Policy Tracking Service, A Service of Thomson Reuters/West
    Issue Brief Health Policy Track Serv; 2011 Jan; ():1-21. PubMed ID: 21374837
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmaceuticals and medical devices: cost savings. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2008 Jan; ():1-27. PubMed ID: 18345555
    [No Abstract]   [Full Text] [Related]  

  • 18. The Food and Drug Administration's role in promoting consistent labels for generic drugs.
    Duke JD; Kesselheim AS
    JAMA Intern Med; 2014 Aug; 174(8):1213-4. PubMed ID: 24957047
    [No Abstract]   [Full Text] [Related]  

  • 19. Substituting generic drugs: state roles.
    Cauchi R
    NCSL Legisbrief; 2009; 17(25):1-2. PubMed ID: 19526654
    [No Abstract]   [Full Text] [Related]  

  • 20. Good law from tragic facts--Congress, the FDA, and preemption.
    Annas GJ
    N Engl J Med; 2009 Sep; 361(12):1206-11. PubMed ID: 19759383
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.